Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Karlo Perica

Karlo Perica

MD, PhD

Memorial Sloan Kettering Cancer Center

The future of in vivo CAR T-cell therapy

The future of in vivo CAR T-cell therapy

Karlo Perica • 3 Nov 2025

How off-the-shelf cellular therapies may change the treatment landscape in myeloma

How off-the-shelf cellular therapies may change the treatment landscape in myeloma

Karlo Perica • 3 Nov 2025

Investigating the efficacy of allogeneic and in vivo CAR T-cell therapies in myeloma

Investigating the efficacy of allogeneic and in vivo CAR T-cell therapies in myeloma

Karlo Perica • 3 Nov 2025

Off-the-shelf cellular therapy approaches in myeloma: allo and in vivo CARs

Off-the-shelf cellular therapy approaches in myeloma: allo and in vivo CARs

Karlo Perica • 3 Nov 2025

CAR-T for ALL: bridging options and choices

CAR-T for ALL: bridging options and choices

Karlo Perica • 2 Jun 2019

CAR-T for ALL: the impact of bridging therapy

CAR-T for ALL: the impact of bridging therapy

Karlo Perica • 2 Jun 2019

Characterizing bridging strategies for CAR T-cell therapy

Characterizing bridging strategies for CAR T-cell therapy

Karlo Perica • 2 Jun 2019